AOP Orphan Announces Leadership Changes to Advance Long Term Strategic Direction27. 8. 2021
AOP Orphan Pharmaceuticals presents latest analysis on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the prestigious European Hematology Association (EHA) Annual Meeting 20201. 7. 2021
Silver Export Award presented to AOP Orphan9. 4. 2021
"AOP Orphan is the European pioneer in Orphan Diseases unconditionally committed to bringing not only drugs but full treatment support to patients with rare diseases."
"AOP Orphan having international expertise in pharmaceutical and clinical development as well as distribution and marketing of drugs in the rare disease area offers flexible solutions for in- and out-licensing partnerships."
"As a company, we are small enough to be really close to our patients, yet we are large enough to be able to provide them high-quality, personalized customer care."